Related Experiment Videos
Antifungal treatment strategy in leukemia patients
1Department of Medicine-Hematology/Oncology, University of Münster, Federal Republic of Germany.
Abstract:
Among the opportunistic infections in patients with leukemias systemic fungal infections contribute a major part if not the majority. This results from autopsy data and is supported clinically when using new criteria by imaging techniques, while microbiological documentation shows a low sensitivity in this situation. Those lessons require a change in strategy toward an earlier and empiric use of systemic antifungal drugs in the frequent infections appearing as fever of unknown origin. By its high systemic activity and low toxicity Fluconazole facilitates this approach. Amphotericin B with 5-Flucytosine remain as the most established standard. Liposomal Amphotericin B allowing higher dosage by lower toxicity appears effective as salvage treatment especially in aspergillosis which also responds to Itraconazole available as oral formulation so far.
Insights
Systemic fungal infections are a major threat in leukemia patients. Early empiric antifungal therapy, particularly with fluconazole, is recommended due to low diagnostic sensitivity and high infection rates.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Opportunistic fungal infections pose a significant risk to leukemia patients.
- Autopsy data and clinical imaging confirm the high prevalence of these infections.
- Microbiological diagnostic methods often exhibit low sensitivity in detecting fungal infections.
Purpose of the Study:
- To highlight the need for a strategic shift in managing fungal infections in leukemia.
- To advocate for earlier and empiric use of systemic antifungal drugs.
- To discuss the role of specific antifungal agents in this patient population.
Main Methods:
- Review of autopsy data and clinical findings.
- Evaluation of diagnostic sensitivity of microbiological techniques.
- Assessment of systemic antifungal drug efficacy and toxicity.
Main Results:
- Systemic fungal infections are a major cause of mortality in leukemia.
- Low sensitivity of current diagnostic methods necessitates a change in strategy.
- Fluconazole offers high systemic activity and low toxicity, facilitating empiric treatment.
- Amphotericin B with 5-Flucytosine remain established standards.
- Liposomal Amphotericin B and Itraconazole show promise, especially for aspergillosis.
Conclusions:
- An earlier, empiric approach to antifungal therapy is crucial for leukemia patients.
- Fluconazole is a viable option for early empiric treatment due to its favorable profile.
- Established standards and newer agents like liposomal Amphotericin B and Itraconazole play key roles in treatment and salvage therapy.